TP53 mutations are detected in 6-21% of MDS patients at diagnosis, predominantly as missense mutations. However, the extent of TP53 tumor suppressor activity loss varies considerably (7, 9, 13). This evidence concerns the gene TP53 and myelodysplastic syndrome.